Currently, there are 55.16M common shares owned by the public and among those 19.30M shares have been available to trade.
The company’s stock has a 5-day price change of -77.46% and -90.44% over the past three months. OMGA shares are trading -85.52% year to date (YTD), with the 12-month market performance down to -96.99% lower. It has a 12-month low price of $0.10 and touched a high of $4.46 over the same period. OMGA has an average intraday trading volume of 1.13 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -74.37%, -84.29%, and -92.30% respectively.
Institutional ownership of Omega Therapeutics Inc (NASDAQ: OMGA) shares accounts for 23.63% of the company’s 55.16M shares outstanding.
It has a market capitalization of $5.98M and a beta (3y monthly) value of 1.72. The earnings-per-share (ttm) stands at -$1.33. Price movements for the stock have been influenced by the stock’s volatility, which stands at 65.79% over the week and 28.73% over the month.
Analysts forecast that Omega Therapeutics Inc (OMGA) will achieve an EPS of -0.28 for the current quarter, -0.28 for the next quarter and -1.2 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.29 while analysts give the company a high EPS estimate of -0.29. Comparatively, EPS for the current quarter was -0.37 a year ago. Earnings per share for the fiscal year are expected to decrease by -26.67%, and -6.14% over the next financial year.
Raymond James coverage for the Omega Therapeutics Inc (OMGA) stock in a research note released on June 18, 2024 offered a Outperform rating with a price target of $12. Jefferies was of a view on May 25, 2023 that the stock is Buy, while H.C. Wainwright gave the stock Buy rating on December 08, 2022, issuing a price target of $11. Chardan Capital Markets on their part issued Buy rating on September 23, 2022.
